Clinical trial NCT04101201 - References

Chronic Venous Disease — Clinical Trial to Assess the Efficacy of µSmin® Plus

Citation(s)

•   Bakhtiari M, Panahi Y, Ameli J, Darvishi B
  Protective effects of flavonoids against Alzheimer's disease-related neural dysfunctions. Biomed Pharmacother. 2017 Sep;93:218-229. doi: 10.1016/j.biopha.2017.06.010. Epub 2017 Jun 20. Review.
•   Belczak SQ, Sincos IR, Campos W, Beserra J, Nering G, Aun R
  Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. Phlebology. 2014 Aug;29(7):454-60. doi: 10.1177/0268355513489550. Epub 2013 May 16.
•   Carpentier PH, Maricq HR, Biro C, Ponçot-Makinen CO, Franco A
  Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France. J Vasc Surg. 2004 Oct;40(4):650-9.
•   Freag MS, Elnaggar YS, Abdallah OY
  Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomedicine. 2013;8:2385-97. doi: 10.2147/IJN.S45231. Epub 2013 Jul 3.
•   Heinen M, Borm G, van der Vleuten C, Evers A, Oostendorp R, van Achterberg T
  The Lively Legs self-management programme increased physical activity and reduced wound days in leg ulcer patients: Results from a randomized controlled trial. Int J Nurs Stud. 2012 Feb;49(2):151-61. doi: 10.1016/j.ijnurstu.2011.09.005. Epub 2011 Sep 28.
•   Kakkos SK, Nicolaides AN
  Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018 Apr;37(2):143-154. doi: 10.23736/S0392-9590.18.03975-5. Epub 2018 Jan 31. Review.
•   Lebeau J, Furman C, Bernier JL, Duriez P, Teissier E, Cotelle N
  Antioxidant properties of di-tert-butylhydroxylated flavonoids. Free Radic Biol Med. 2000 Nov 1;29(9):900-12.
•   Lichota A, Gwozdzinski L, Gwozdzinski K
  Therapeutic potential of natural compounds in inflammation and chronic venous insufficiency. Eur J Med Chem. 2019 Aug 15;176:68-91. doi: 10.1016/j.ejmech.2019.04.075. Epub 2019 May 6. Review.
•   Malone PC, Agutter PS
  To what extent might deep venous thrombosis and chronic venous insufficiency share a common etiology? Int Angiol. 2009 Aug;28(4):254-68. Review.
•   Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X
  Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Apr 6;4:CD003229. doi: 10.1002/14651858.CD003229.pub3. Review.
•   Milano G, Leone S, Fucile C, Zuccoli ML, Stimamiglio A, Martelli A, Mattioli F
  Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports. J Med Case Rep. 2014 Jun 16;8:194. doi: 10.1186/1752-1947-8-194.
•   Onida S, Davies AH
  Predicted burden of venous disease. Phlebology. 2016 Mar;31(1 Suppl):74-9. doi: 10.1177/0268355516628359. Review.
•   Panche AN, Diwan AD, Chandra SR
  Flavonoids: an overview. J Nutr Sci. 2016 Dec 29;5:e47. doi: 10.1017/jns.2016.41. eCollection 2016. Review.
•   Rabe E, Guex JJ, Morrison N, Ramelet AA, Schuller-Petrovic S, Scuderi A, Staelens I, Pannier F
  Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. Phlebology. 2013 Sep;28(6):308-19. doi: 10.1177/0268355512471929. Epub 2013 May 6. Review.
•   Robertson L, Evans C, Fowkes FG
  Epidemiology of chronic venous disease. Phlebology. 2008;23(3):103-11. doi: 10.1258/phleb.2007.007061.
•   Russo R, Chandradhara D, De Tommasi N
  Comparative Bioavailability of Two Diosmin Formulations after Oral Administration to Healthy Volunteers. Molecules. 2018 Aug 29;23(9). pii: E2174. doi: 10.3390/molecules23092174.
•   Russo R, Mancinelli A, Ciccone M, Terruzzi F, Pisano C, Severino L
  Pharmacokinetic Profile of µSMIN Plus™, a new Micronized Diosmin Formulation, after Oral Administration in Rats. Nat Prod Commun. 2015 Sep;10(9):1569-72.
•   Vuylsteke ME, Thomis S, Guillaume G, Modliszewski ML, Weides N, Staelens I
  Epidemiological study on chronic venous disease in Belgium and Luxembourg: prevalence, risk factors, and symptomatology. Eur J Vasc Endovasc Surg. 2015 Apr;49(4):432-9. doi: 10.1016/j.ejvs.2014.12.031. Epub 2015 Feb 18.
•   Wilson D, Wakefield M, Owen N, Roberts L
  Characteristics of heavy smokers. Prev Med. 1992 May;21(3):311-9.
•   Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM, Kirienko AI
  Prevalence and Risk Factors for Chronic Venous Disease in the General Russian Population. Eur J Vasc Endovasc Surg. 2017 Dec;54(6):752-758. doi: 10.1016/j.ejvs.2017.08.033. Epub 2017 Oct 12.

Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy of µSmin® Plus (Dietary Supplement) in Chronic Venous Insufficiency Symptoms Relief

Details for clinical trial NCT04101201